Cue Biopharma
CUE
75 hedge funds and large institutions have $17.1M invested in Cue Biopharma in 2024 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 20 closing their positions.
1,450% more call options, than puts
Call options by funds: $279K | Put options by funds: $18K
1% more funds holding
Funds holding: 74 → 75 (+1)
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
0.26% less ownership
Funds ownership: 1.21% → 0.95% (-0.26%)
36% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 22
45% less capital invested
Capital invested by funds: $31M → $17.1M (-$13.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GLA
Good Life Advisors
Reading,
Pennsylvania
|
+$371K |
| 2 |
Goldman Sachs
New York
|
+$364K |
| 3 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$253K |
| 4 |
Millennium Management
New York
|
+$217K |
| 5 |
BL
Bleichroeder LP
New York
|
+$176K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.45M |
| 2 |
State Street
Boston,
Massachusetts
|
-$961K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$571K |
| 4 |
Renaissance Technologies
New York
|
-$518K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$415K |
CUE Hedge Fund Activity: Q2 2024 in Review
75 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2024, worth a combined $17.1M — down 45% from $31M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new CUE positions and 20 closed out — a net gain of 1 holder — while 14 added to existing stakes and 22 trimmed.
The largest buyer was Good Life Advisors, adding an estimated $371K. The largest seller was BlackRock, cutting an estimated $2.45M.
- 75 institutional investors held Cue Biopharma (CUE) as of Q2 2024, up from 74 in Q1 2024.
- Funds reported $17.1M of Cue Biopharma stock for Q2 2024, down 45% quarter-over-quarter.
- 21 funds opened new Cue Biopharma positions in Q2 2024 and 20 closed out, a net change of +1 holder.
- The largest Cue Biopharma buyer in Q2 2024 was Good Life Advisors, an estimated $371K added.
- The largest Cue Biopharma seller in Q2 2024 was BlackRock, an estimated $2.45M sold.
Based on aggregated 13F filings for Q2 2024.